Christina Louise Costantino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 2 | 2021 | 1111 | 0.860 |
Why?
|
| Ribs | 1 | 2021 | 252 | 0.660 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2021 | 97 | 0.650 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 94 | 0.650 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 123 | 0.600 |
Why?
|
| Gastrectomy | 3 | 2019 | 679 | 0.590 |
Why?
|
| Laparoscopy | 2 | 2020 | 2147 | 0.570 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 1423 | 0.560 |
Why?
|
| Trachea | 2 | 2021 | 1082 | 0.540 |
Why?
|
| Laryngectomy | 1 | 2017 | 243 | 0.510 |
Why?
|
| Laryngostenosis | 1 | 2017 | 167 | 0.510 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 626 | 0.460 |
Why?
|
| Tracheostomy | 1 | 2017 | 425 | 0.440 |
Why?
|
| Antigens, Surface | 3 | 2010 | 1608 | 0.370 |
Why?
|
| Deoxycytidine Kinase | 2 | 2010 | 11 | 0.360 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 13262 | 0.310 |
Why?
|
| Deoxycytidine | 2 | 2010 | 873 | 0.310 |
Why?
|
| RNA-Binding Proteins | 3 | 2010 | 1894 | 0.270 |
Why?
|
| General Surgery | 1 | 2015 | 1678 | 0.220 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2009 | 1724 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 6 | 2010 | 5351 | 0.200 |
Why?
|
| Fundoplication | 1 | 2020 | 144 | 0.160 |
Why?
|
| Sexual Harassment | 1 | 2019 | 80 | 0.160 |
Why?
|
| Nitrogen | 1 | 2020 | 350 | 0.160 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 277 | 0.160 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2009 | 117 | 0.160 |
Why?
|
| Smoking | 1 | 2015 | 9073 | 0.150 |
Why?
|
| Bronchi | 1 | 2021 | 848 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 640 | 0.140 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 348 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 1791 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3529 | 0.130 |
Why?
|
| New Orleans | 1 | 2015 | 27 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2020 | 638 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2021 | 65017 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 2821 | 0.110 |
Why?
|
| Robotics | 1 | 2021 | 874 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1303 | 0.100 |
Why?
|
| Vitamin K 2 | 1 | 2009 | 47 | 0.090 |
Why?
|
| Vitamin K 1 | 1 | 2009 | 47 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3202 | 0.080 |
Why?
|
| Thymidylate Synthase | 1 | 2009 | 74 | 0.080 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 92 | 0.080 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 1648 | 0.080 |
Why?
|
| Smad4 Protein | 1 | 2009 | 191 | 0.070 |
Why?
|
| Education, Medical | 1 | 2019 | 1727 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2008 | 252 | 0.070 |
Why?
|
| Humans | 22 | 2023 | 760621 | 0.070 |
Why?
|
| Cytarabine | 1 | 2009 | 696 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2773 | 0.070 |
Why?
|
| Genome, Human | 1 | 2020 | 4417 | 0.070 |
Why?
|
| Caspases | 1 | 2009 | 878 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2009 | 713 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 749 | 0.070 |
Why?
|
| Boston | 1 | 2018 | 9280 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2023 | 80372 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5251 | 0.060 |
Why?
|
| Time Factors | 3 | 2018 | 40165 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2008 | 963 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2008 | 1516 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2009 | 1631 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 5253 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 1052 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2009 | 4122 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 8515 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 219994 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 6131 | 0.050 |
Why?
|
| Physicians | 1 | 2019 | 4591 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2010 | 12766 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 2210 | 0.040 |
Why?
|
| Female | 8 | 2021 | 391270 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1529 | 0.040 |
Why?
|
| Middle Aged | 6 | 2020 | 220352 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5870 | 0.040 |
Why?
|
| Alendronate | 1 | 2020 | 173 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4291 | 0.040 |
Why?
|
| Cell Line, Tumor | 6 | 2010 | 16939 | 0.040 |
Why?
|
| Mutation | 3 | 2020 | 29932 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 163 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3707 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11152 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 24123 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2221 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2008 | 1943 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 4490 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2020 | 711 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15697 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12808 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 3075 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2019 | 466 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10446 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 1818 | 0.030 |
Why?
|
| Apoptosis | 1 | 2009 | 9501 | 0.030 |
Why?
|
| Lung | 2 | 2023 | 9994 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 169152 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 9585 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 74359 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 11071 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6315 | 0.020 |
Why?
|
| Recurrence | 1 | 2023 | 8482 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2050 | 0.020 |
Why?
|
| Melanoma | 1 | 2009 | 5697 | 0.020 |
Why?
|
| Male | 5 | 2020 | 359744 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 5799 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2020 | 2560 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2009 | 189 | 0.020 |
Why?
|
| Thymidine | 1 | 2009 | 299 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 465 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2009 | 159 | 0.020 |
Why?
|
| Uridine | 1 | 2009 | 143 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2009 | 331 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2009 | 402 | 0.020 |
Why?
|
| Yeasts | 1 | 2009 | 279 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 616 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 468 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 551 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13630 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 23376 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8803 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1649 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 6479 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9276 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3323 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2010 | 1617 | 0.010 |
Why?
|
| Cadherins | 1 | 2009 | 898 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4573 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 5039 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8469 | 0.010 |
Why?
|
| RNA Interference | 1 | 2010 | 2846 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1612 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20080 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2010 | 4264 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2009 | 2934 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 2943 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1728 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 21025 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3157 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4107 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 5797 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6068 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8313 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 9335 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4713 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 12446 | 0.010 |
Why?
|
| Alleles | 1 | 2009 | 6898 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10827 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41335 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 5785 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7588 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 17624 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 12960 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5643 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 81208 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9411 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9467 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7850 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 6853 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 167963 | 0.000 |
Why?
|